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Abstract
Abnormalities in liver function tests, including transient 
and self-limiting hypertransaminasemia, cholestatic 
disease and hepatitis, can develop during treatment 
with anti-tumour-necrosis-factor (TNF) therapy. The 
optimal management of liver injury related to anti-
TNF therapy is still a matter of debate. Although some 
authors recommend discontinuing treatment in case 
of both a rise of alanine aminotransferase more than 
5 times the upper limit of normal, or the occurrence 
of jaundice, there are no standard guidelines for the 
management of anti-TNF-related liver injury. Biblio-
graphical searches were performed in PubMed, using 
the following key words: inflammatory bowel disease 
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(IBD); TNF inhibitors; hypertransaminasemia; drug-
related liver injury; infliximab. According to published 
data, elevation of transaminases in patients with IBD 
treated with anti-TNF is a common finding, but resolu-
tion appears to be the usual outcome. Anti-TNF agents 
seem to be safe with a low risk of causing severe drug-
related liver injury. According to our centre experience, 
we found that hypertransaminasemia was a common, 
mainly self-limiting finding in our IBD cohort and was 
not correlated to infliximab treatment on both univari-
ate and multivariate analyses. An algorithm for the 
management of liver impairment occurring during anti-
TNF treatment is also proposed and this highlights the 
need of a multidisciplinary approach and suggests liver 
biopsy as a key-point in the management decision in 
case of severe rise of transaminases. However, hepatic 
injury is generally self-limiting and drug withdrawal 
seems to be an exception.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Anti-tumour-necrosis-factor (TNF) agents ap-
pear to be safe with a low risk of causing severe liver 
injury. Standard guidelines for the management of 
anti-TNF-related liver injury are lacking. Our approach, 
based on evidence from literature and our centre ex-
perience, highlights the need of a multidisciplinary ap-
proach and suggests liver biopsy as a key-point in the 
management decision. We particularly highlight that 
continuation of the anti-TNF treatment is usually pos-
sible, in view of the rarity of severe liver injury and the 
lack of alternative medical options in case of severe ac-
tive inflammatory bowel disease.
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INTRODUCTION
Inflammatory bowel diseases (IBD), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC), are a heterogenous 
group of  chronic immune disorders of  unclear aetiology. 
There are approximately 240000 patients with IBD in the 
United Kingdom (UC: 243/100000 = 146000 people; 
CD: 145/100000 = 87000 people)[1]. People affected by 
IBD show a life-time risk for surgery of  70%-80% and 
20%-30% for CD and UC, respectively[2-6].
Therapy for IBD is a rapidly evolving field with many 
new biological agents that have shown promising results. 
Therapeutic options for IBD include corticosteroids, 
aminosalicylates, antibiotics (i.e., metronidazole and cip-
rofloxacin), thiopurines (i.e., azathioprine and mercapto-
purine), methotrexate, ciclosporin, tacrolimus and anti-
tumour necrosis factor (TNF) agents[1].
TNF-α is an integral pro-inflammatory cytokine, 
which is produced by macrophages and promotes the re-
lease of  other inflammatory cytokines. It plays a key role 
in immune defense against infections and contributes to 
the development of  certain cancers[7,8]. In view of  its well 
known pro-inflammatory action, TNF-α has been identi-
fied as a key therapeutic target for treating inflammatory 
diseases including IBD[8].
The United States Food and Drug Administration 
(FDA) has approved several anti-TNF-α agents, such as 
infliximab (Remicade, Janssen), adalimumab (Humira, 
Abbott), etanercept (Enbrel, Amgen), certolizumab 
(Cimzia, UCB), and golimumab (Simponi, Janssen), for 
the treatment of  several immunological conditions[9-13].
Some placebo-controlled trials have shown that inflix-
imab[14,15], adalimumab[16-18] and certolizumab pegol[19] are 
efficacious in the treatment of  moderate-to-severe CD, 
both when used as first-line therapy and in patients who 
did not respond to standard treatment. Anti-TNF agents 
have been reported to achieve disease remission, to main-
tain the treatment response[15,20-22], to allow tapering of  
glucocorticoids[15,16] and to promote mucosal healing[23]. 
Infliximab is also effective in the treatment of  fistulizing 
CD[24] and, according to current data, early treatment with 
infliximab or adalimumab (within 4 wk after surgery) 
could prevent histologic and endoscopic recurrence after 
ileal resection[25,26].
As concerns UC, some randomized, controlled tri-
als have shown that infliximab[27], adalimumab[28,29] and 
golimumab[30] can induce and maintain clinical remission 
in patients with moderate-to-severe disease activity who 
failed to respond to standard therapy. In particular, data 
suggest that infliximab reduces the rate of  colectomy 
after one year from 17% in the placebo group to 10% 
in those treated with infliximab[31]. Adverse effects of  
anti-TNF agents include acute infusion reactions (10%), 
severe infusion reactions (less than 1%), including ana-
phylaxis, convulsions, erythematous rash, and hypoten-
sion, serum sickness and leukocytoclastic vasculitis (< 1 
per 1000 patients), neurologic events (e.g., demyelinating 
neuropathy) (< 1 event per 1000 patients), risk of  oppor-
tunistic infections, and reactivation of  latent tuberculosis 
and/or hepatitis B virus (HBV) infection[32]. According to 
some studies, the risk of  specific cancers (i.e., non-Hodg-
kin’s lymphoma, lung cancer, skin cancer, and others) 
may be increased by the combinations of  glucocorticoids, 
immunomodulators, and TNF inhibitors[32].
All of  the TNF-antagonists currently marketed have 
been associated with drug-induced liver injury (DILI)[33,34]. 
According to a FDA post-marketing surveillance pro-
gram, more than 130 reports of  hepatic damage resulting 
from either infliximab or etanercept treatment have been 
reported. Among these, seven cases showed a strong as-
sociation with the anti-TNF agents[35]. Of  relevance, the 
use of  TNF inhibitors has been associated with the risk 
of  reactivation of  viral hepatitis B, although the exact 
underlying mechanism is still far from being fully eluci-
dated. Accordingly, pre-treatment screening for hepatitis 
B is required prior to start anti-TNF therapy and vaccina-
tion should be encouraged in the non-immune high-risk 
patients[36]. In addition, TNF inhibitor therapy may result 
in a wide range of  liver abnormalities, including transient 
and self-limiting hypertransaminasemia, cholestatic dis-
ease and hepatitis.
The optimal management of  liver injury related to 
anti-TNF therapy is still a matter of  debate. Although 
some authors recommend discontinuation of  treatment 
in case of  both a rise of  alanine aminotransferase (ALT) 
of  more than five times the upper limit of  normal (ULN), 
or the occurrence of  jaundice[37-39], at present there are 
no standard guidelines for the management of  anti-TNF-
related liver injury. Herein, we propose an algorithm for 
the management of  liver impairment occurring during 
anti-TNF treatment, according to both current evidence 
from literature and our own centre experience.
LITeRaTURe seaRChes 
Bibliographical searches were performed in PubMed, us-
ing the following key words: inflammatory bowel disease; 
TNF inhibitors; hypertransaminasemia; drug-related liver 
injury; infliximab. Reference lists from studies selected by 
the electronic search were manually searched to identify 
further relevant reports. Reference lists from all available 
review articles, primary studies and proceedings of  major 
meetings were also considered. No language restriction 
was applied.
Regarding our own centre experience, 305 patients 
with a histologically confirmed diagnosis of  IBD were 
retrospectively evaluated. Laboratory and clinical data 
were retrieved from a database at Department of  Gastro-
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enterology, Royal Free Hospital, London. Patients with 
known liver related disease were excluded. Of  these 305 
patients, 176 consecutive patients were treated with inf-
liximab, between 2008 and 2013, at the standard regimen 
dose of  5 mg/kg at weeks 0, 2, 6 and every 8 wk thereaf-
ter. Baseline laboratory parameters were obtained the day 
before infliximab induction and full blood count and liver 
biochemistry were monitored every 8 wk thereafter. Liver 
enzymes were recorded until each patient’s last follow-
up. The same parameters were recorded from a control 
group of  IBD patients, who did not receive any anti-
TNF agent and were matched by gender, type of  IBD 
and duration of  follow-up to the study group.
WhaT Is aLReaDY KNOWN aBOUT 
LIVeR DYsFUNCTION DURING aNTI-TNF 
TReaTMeNT
Elevation of  ALT/AST, usually between 2 and 3xULN is 
not uncommon during anti-TNF treatment with a report-
ed prevalence of  37%-42% compared with 29%-36% 
in control groups[40], but rarely results in liver failure[41]. 
However, liver damage including hepatitis or cholesta-
sis might be a complication of  anti-TNF treatment[42-53] 
and cases of  acute liver failure[54-58], fulminant hepatitis 
B infection[36,57,58] as well as severe liver injury requiring 
emergency liver transplantation have been reported[39,59]. 
Induction of  auto-immune/immuno-mediated hepatitis 
in patients with IBD[60-71] has also been reported. Anti-
TNF hepatitis, although rare, might be a life-threatening 
complication, which needs to be promptly recognized 
and treated. However, according to a recent systematic 
review, these agents are generally considered to be safe in 
the majority of  patients, including those with underlying 
liver disease (i.e., chronic hepatitis C), whereas the risk 
of  activation of  hepatitis B needs to be taken into ac-
count[72,73].
The underlying mechanism for liver toxicity associ-
ated with anti-TNF remains to be elucidated. Pre-existing 
liver disease and concomitant potentially hepatotoxic 
drugs may increase the risk. Infliximab hepatitis seems to 
be sustained by an immuno-mediated mechanism, mim-
icking the characteristics of  autoimmune hepatitis type I, 
although a direct liver damage cannot be ruled out[48,50]. 
Additionally, anti-TNF treatment is known to induce 
lipid profile changes[74-77], which may be reflected in a 
increased risk of  liver steatosis, although the importance 
of  these alterations needs to be clarified in future studies. 
Furthermore, whether infliximab immuno-mediated liver 
injury may lead to chronic disease, or ultimately resolve 
with treatment withdrawal remains to be fully elucidated.
OUR CeNTRe eXPeRIeNCe (MaNUsCRIPT 
IN PRePaRaTION)
According to our centre experience, 176 IBD patients 
were treated with infliximab between 2008 and 2013, 
with a mean duration of  treatment of  23.1 ± 21.7 mo, 
and ALT increase was observed in 69 (39.2%) of  them, 
with spontaneous resolution in 76% of  cases. Approxi-
mately 50% of  these patients were taking immunomodu-
lators. When comparing the 67 patients who had elevated 
transaminases with the 107 patients on infliximab who 
showed persistent normal ALT, there were no statistically 
significant differences in terms of  age, gender, diagnosis 
(UC or CD) and use of  immunomodulators, aminosalicy-
lates or steroids. 36.2% of  patients with abnormal ALT 
during follow-up had elevated transaminases up to one 
year before infliximab induction, compared to 15% of  
those with normal liver enzymes (P = 0.002). The mean 
duration of  anti-TNF treatment was significantly longer 
in patients with abnormal liver enzymes than in the sub-
group of  patients with normal transaminases (29.5 mo vs 
11.5 mo, P < 0.0005). In multivariate analysis, abnormal 
ALT in the subgroup of  patients treated with infliximab 
was significantly associated with elevated ALT prior to 
infliximab induction (OR = 3.854, 95%CI: 1.800-8.251, P 
= 0.001) and longer duration of  infliximab treatment (OR 
= 1.030, 95%CI: 1.013-1.047, P = 0.001).
When considering a whole cohort of  305 IBD pa-
tients (176 patients treated with infliximab and 129 IBD 
patients matched for gender, type of  IBD and length of  
follow-up as a control group), hypetransaminasemia was 
found in 36.4% of  the patients and spontaneous resolu-
tion occurred in 73% of  cases. Univariate and multivari-
ate analysis showed that the treatment with immunomod-
ulators was correlated to increased transaminases (OR = 
2.666, 95%CI: 1.576-4.511, P < 0.001), whilst the use of  
infliximab, steroids or aminosalicylates, age, gender and 
diagnosis were not (P = NS).
Twelve patients treated with infliximab developed 
severe hypertransaminasemia (ALT > 3 x ULN). They 
were all screened for hepatitis A, B, C, for HIV and CMV 
serology and found negative. Immunoglobulin G, ferri-
tin, alpha1- antitrypsin, copper, ceruloplasmin levels and 
coeliac screening were also normal. Alcohol intake was 
excluded. Three patients had positive antinuclear antibod-
ies: one patient had concomitant lupus erythematosus 
(titer 1:80) and the remaining two showed a very low titer 
(1:40). Additionally, as they all had normal immunoglobu-
lins, normal other autoantibodies and only transient hy-
pertransaminasemia, they were not further investigated. A 
liver ultrasound was performed in all the patients, show-
ing fatty liver in 4 patients. A liver biopsy was done in 3 
out of  12 infliximab patients with persistent severe hyper-
transaminasemia and liver histopathology was suggestive 
of  DILI in 2 patients and non-alcoholic steatohepatitis in 
the remaining one. Of  the two patients with established 
DILI one was on infliximab monotherapy (which was 
discontinued) and one on combination of  infliximab and 
6-mercaptopurine (6-MP, which was subsequently dis-
continued). The 12 patients were carefully monitored and 
hypertransaminasemia spontaneously resolved in 11/12 
patients without discontinuation of  anti-TNF treatment, 
whilst infliximab was stopped only in the patient with a 
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WhaT We sUGGesT
In view of  the available literature and our own centre’s ex-
perience we suggest the following algorithm for the man-
agement of  liver impairment occurring during anti-TNF 
treatment (Figure 1).
What information should be given to patients?
All patients should be aware of  the potential problem of  
hepatotoxicity and should seek urgent medical advice in 
case they feel unwell or notice the presence of  jaundice. 
Moreover, alcohol intake should be reduced, as per cur-
rent recommendations[78].
What to do before starting anti-TNF medication?
Before starting anti-TNF treatment, all the patients 
should be investigated for previous liver disease including 
viral chronic hepatitis, auto-immune disorders, non alco-
holic fatty liver disease, history of  alcohol intake/abuse 
and/or of  illicit drug use. A baseline complete blood test 
including liver function tests and screening for hepatitis B, 
C and for HIV is advisable. Risk of  reactivation of  hepa-
titis B should be taken into account and HBV carriers 
confirmed diagnosis of  DILI on liver biopsy. 
CURReNT ReCOMMeNDaTIONs 
ReGaRDING MONITORING LIVeR 
FUNCTION WITh aNTI-TNF TheRaPY
The optimal management of  liver injury related to anti-
TNF therapy is still a matter of  debate and a multidisci-
plinary management is required.
According to previous case reports and a recent 
consensus statement[39,62], it was recommended that inf-
liximab therapy should be avoided or discontinued in pa-
tients with a raise of  aminotransferases more than three 
times the ULN and that liver function tests should be 
determined prior to anti-TNF treatment, after induction 
treatment and at least every four months while on main-
tenance treatment. However, the application of  the above 
mentioned precautions failed in systematic prevention of  
the development of  severe liver injury[54]. Furthermore, 
such stringent criteria might deny anti-TNF to many pa-
tients who might benefit from it due to the lack of  alter-
native therapeutic options.
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Investigations for previous liver disease (chronic 
hepatitis, auto-immune disorders, non alcoholic fatty 
liver disease, history of alcohol intake, drug history). 
Baseline complete blood test with liver function tests 
and screening for hepatitis B, C and for HIV 
HBV carriers should receive primary prophylaxis or 
should be carefully monitored
Anti-TNF treatment
Check LFTs every two weeks for eight weeks
LFTs normal LFTs abnormal
Monitor LFTs every 8 wk 
for the duration of therapy
Isolated raise of ALT < 3 
ULN without jaundice
Raise of ALT > 3 
ULN +/- bilirubin 
increase or 
jaundice onset
Check LFTs every two 
weeks up to resolution
Rule out all possible causes of elevated 
transaminases (viral hepatitis, alcohol 
intake, autoimmunity, drugs, coeliac 









Figure 1  Proposed algorithm for the management of liver abnormalities occurring during anti-tumour necrosis factor treatment. TNF: Tumour necrosis 
factor; ALT: Alanine aminotransferase; LFT: Liver function tests; NAFLD: Non alcoholic fatty liver disease; US: Ultrasound; HBV: Hepatitis B virus; ULN: Upper limit of 
normal; HIV: Human immunodeficiency virus.
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should receive primary prophylaxis or should be carefully 
monitored[79].
What to do after starting anti-TNF medication?
Liver function tests should be regularly performed after 
starting anti-TNF therapy, every two weeks for the first 
eight weeks, and eight weekly thereafter.
In those patients receiving anti-TNF therapy and with 
abnormal transaminase levels, the first step is to rule out 
all other possible causes of  hypetransaminasemia, includ-
ing viral hepatitis, history of  alcohol abuse, auto-immune 
disorders, coeliac disease, non alcoholic fatty liver disease 
and drug history.
When facing with an increase of  ALT < 3 x ULN 
repeated monitoring is advisable, even if  further ac-
tion might not be required. On the contrary, in case of  
marked elevation of  ALT levels (> 3 x ULN) or alarm 
signs (e.g., rapid onset of  jaundice), a multidisciplinary 
approach is required. Further tests, including a liver ultra-
sound scan, should be requested and in case of  persistent 
elevated transaminases, a liver biopsy might be useful 
to confirm the diagnosis of  DILI or to exclude other 
potential aetiologies, possibly suitable for specific treat-
ment. Of  course, DILI represents a relevant cause of  
liver impairment with significant morbidity and mortal-
ity[80]. Early diagnosis of  DILI might be difficult[81,82] and 
is usually by exclusion[83]. Liver histology is considered 
helpful in strengthening the diagnosis or excluding other 
potential causes of  liver injury and a recent study provid-
ed a standardized framework for systematic review and 
classification of  pathological changes in liver biopsies[84]. 
Discontinuation of  the treatment might be considered, 
but the decision should be tailored to each single patient, 
given the rarity of  severe liver injury and the possibility 
of  a spontaneous resolution of  the elevation of  trans-
aminase levels. According to our centre experience, the 
spontaneous resolution of  hypetransaminasemia despite 
continuing anti-TNF treatment, might suggest that severe 
liver injury due to anti-TNF therapy, although possible, is 
rare.
CONCLUsION
In conclusion, we have highlighted the lack of  standard 
guidelines for the management of  anti-TNF-related liver 
injury and, differently from previous reviews, we have 
proposed a possible algorithm for its management ac-
cording to both evidence from literature and our own 
centre’s experience. Innovative aspects of  our approach, 
which are not present in the algorithm previously sug-
gested by Mancini et al[62], include: (1) a multidisciplinary 
approach for this subgroup of  patients, which requires 
a close interaction between Hepatologists and Gastro-
enterolgists; (2) the continuation of  the anti-TNF treat-
ment which is usually possible, in view of  the rarity of  
severe liver injury, the high percentage of  spontaneous 
regression of  the hypertransaminasemia and the lack of  
alternative medical options in case of  severe active IBD. 
The decision should be tailored to each single patient; (3) 
a liver biopsy which is advisable prior to stopping treat-
ment because it might be useful to confirm the diagnosis 
of  DILI or to exclude other possible aetiologies which 
might benefit from specific therapy; and (4) the exclusion 
of  other possible causes of  hypetransaminasemia which 
should also include history of  alcohol intake, coeliac 
disease screening[85] and careful evaluation of  drug intake 
(other than anti-TNF treatment).
In summary, elevation of  ALT in patients with IBD 
treated with anti-TNF is a common finding, but, even in 
case of  moderate or severe ALT abnormalities, resolution 
appears to be the usual outcome. Anti-TNF agents ap-
pear to be safe with a low risk of  causing severe DILI. In 
case of  severe hypertransaminasemia a multidisciplinary 
approach is recommended but drug withdrawal seems to 
be an exception due to the rarity of  severe liver injury.
ReFeReNCes
1 Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll 
R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho 
GT, Satsangi J, Bloom S. Guidelines for the management of 
inflammatory bowel disease in adults. Gut 2011; 60: 571-607 
[PMID: 21464096 DOI: 10.1136/gut.2010.224154]
2 Munkholm P, Langholz E, Davidsen M, Binder V. Disease 
activity courses in a regional cohort of Crohn’s disease 
patients. Scand J Gastroenterol 1995; 30: 699-706 [PMID: 
7481535]
3 Langholz E, Munkholm P, Davidsen M, Binder V. Course of 
ulcerative colitis: analysis of changes in disease activity over 
years. Gastroenterology 1994; 107: 3-11 [PMID: 8020674]
4 Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal 
cancer risk and mortality in patients with Crohn’s disease. 
Gastroenterology 1993; 105: 1716-1723 [PMID: 8253348]
5 Lennard-Jones JE, Shivananda S. Clinical uniformity of 
inflammatory bowel disease a presentation and during the 
first year of disease in the north and south of Europe. EC-
IBD Study Group. Eur J Gastroenterol Hepatol 1997; 9: 353-359 
[PMID: 9160197]
6 Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Sur-
vival and cause-specific mortality in ulcerative colitis: follow-
up of a population-based cohort in Copenhagen County. 
Gastroenterology 2003; 125: 1576-1582 [PMID: 14724807]
7 Park HJ, Ranganathan P. TNF-alpha antagonism and cancer 
risk in rheumatoid arthritis: is continued vigilance war-
ranted? Discov Med 2012; 13: 229-234 [PMID: 22463799]
8 Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van 
Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds 
A, Emery P. Malignancies associated with tumour necrosis 
factor inhibitors in registries and prospective observational 
studies: a systematic review and meta-analysis. Ann Rheum 
Dis 2011; 70: 1895-1904 [PMID: 21885875 DOI: 10.1136/
ard.2010.149419]
9 Humira (adalimumab) [U.S. package insert and full pre-
scribing information]. Abbott Laboratories. Last revised 
December 2011. Accessed January 28, 2013. Available from: 
URL: http://www.accessdata.fda.gov/drugsatfda_docs/
label/2011/125057s0276lbl.pdf.
10 Enbrel (etanercept) [U.S. package insert and full prescribing 
information]. Amgen Wyeth, manufactured by Immunex. 
Last revised September 2011. Accessed January 28, 2013. 
Available from: URL: http://www.accessdata.fda.gov/
drugsatfda_docs/label/2009/103795s5415lbl.pdf.
11 Remicade (infliximab) [U.S. package insert and full prescrib-
ing information]. Janssen Biotech, Inc. Last revised October 
2011. Accessed January 28, 2013. Available from: URL: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/
17356 December 14, 2014|Volume 20|Issue 46|WJG|www.wjgnet.com
Rossi RE et al . Tumour-necrosis-factor inhibitors and liver
2011/103772s5295lbl.pdf.
12 Cimzia (certolizumab) [U.S. package insert and full prescrib-
ing information].UCB Inc. Last revised April 2012. Accessed 
January 28, 2013. Available from: URL: http://www.access-
data. fda.gov/drugsatfda_docs/label/2012/125160s0174lbl.
pdf.
13 Simponi (golimumab) [U.S. package insert and full pre-
scribing information]. Janssen Biotech, Inc. Last revised 
December 2011. Accessed January 28, 2013. Available from: 
URL: http: //www.accessdata.fda.gov/drugsatfda_docs/
label/2011/125289s0064lbl.pdf.
14 Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present 
DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. 
A short-term study of chimeric monoclonal antibody cA2 
to tumor necrosis factor alpha for Crohn’s disease. Crohn’s 
Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035 
[PMID: 9321530]
15 Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Sch-
reiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, 
Bao W, Rutgeerts P. Maintenance infliximab for Crohn’s 
disease: the ACCENT I randomised trial. Lancet 2002; 359: 
1541-1549 [PMID: 12047962]
16 Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer 
SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent 
JD, Pollack PF. Adalimumab for maintenance of clinical 
response and remission in patients with Crohn’s disease: 
the CHARM trial. Gastroenterology 2007; 132: 52-65 [PMID: 
17241859]
17 Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas 
M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human 
anti-tumor necrosis factor monoclonal antibody (adalimum-
ab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 
2006; 130: 323-333; quiz 591 [PMID: 16472588]
18 Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel 
JF, Panaccione R, D’Haens G, Li J, Rosenfeld MR, Kent JD, 
Pollack PF. Adalimumab induction therapy for Crohn dis-
ease previously treated with infliximab: a randomized trial. 
Ann Intern Med 2007; 146: 829-838 [PMID: 17470824]
19 Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts 
P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol 
for the treatment of Crohn’s disease. N Engl J Med 2007; 357: 
228-238 [PMID: 17634458]
20 Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen 
OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ. 
Maintenance therapy with certolizumab pegol for Crohn’s 
disease. N Engl J Med 2007; 357: 239-250 [PMID: 17634459]
21 Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, 
Hanauer SB, Bloomfield R, Sandborn WJ. Continuous thera-
py with certolizumab pegol maintains remission of patients 
with Crohn’s disease for up to 18 months. Clin Gastroenterol 
Hepatol 2010; 8: 600-609 [PMID: 20117244 DOI: 10.1016/
j.cgh.2010.01.014]
22 Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas 
M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, 
Li J, Pollack PF. Adalimumab for maintenance treatment of 
Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 
56: 1232-1239 [PMID: 17299059]
23 Neurath MF, Travis SP. Mucosal healing in inflammatory 
bowel diseases: a systematic review. Gut 2012; 61: 1619-1635 
[PMID: 22842618]
24 Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan 
BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, 
Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, 
Marsters PA, Travers SB, Blank MA, van Deventer SJ. Inflix-
imab maintenance therapy for fistulizing Crohn’s disease. N 
Engl J Med 2004; 350: 876-885 [PMID: 14985485]
25 Aguas M, Bastida G, Cerrillo E, Beltrán B, Iborra M, Sán-
chez-Montes C, Muñoz F, Barrio J, Riestra S, Nos P. Adali-
mumab in prevention of postoperative recurrence of Crohn’
s disease in high-risk patients. World J Gastroenterol 2012; 18: 
4391-4398 [PMID: 22969204 DOI: 10.3748/wjg.v18.i32.4391]
26 Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida 
N, Ohda Y, Yokoyama Y, Iimuro M, Takeda N, Kato K, 
Kikuyama R, Nagase K, Hori K, Nakamura S, Miwa H, Mat-
sumoto T. Scheduled infliximab monotherapy to prevent 
recurrence of Crohn’s disease following ileocolic or ileal re-
section: a 3-year prospective randomized open trial. Inflamm 
Bowel Dis 2012; 18: 1617-1623 [PMID: 22081474 DOI: 10.1002/
ibd.21928]
27 Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson 
A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lich-
tenstein GR, de Villiers WJ, Present D, Sands BE, Colombel 
JF. Infliximab for induction and maintenance therapy for 
ulcerative colitis. N Engl J Med 2005; 353: 2462-2476 [PMID: 
16339095]
28 Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, 
Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe 
MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalim-
umab for induction of clinical remission in moderately to 
severely active ulcerative colitis: results of a randomised 
controlled trial. Gut 2011; 60: 780-787 [PMID: 21209123 DOI: 
10.1136/gut.2010.221127]
29 Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’
Haens G, Wolf DC, Kron M, Tighe MB, Lazar A, Thakkar 
RB. Adalimumab induces and maintains clinical remission 
in patients with moderate-to-severe ulcerative colitis. Gas-
troenterology 2012; 142: 257-65.e1-3 [PMID: 22062358 DOI: 
10.1053/j.gastro.2011.10.032]
30 Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, 
Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, 
Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P. Subcu-
taneous golimumab induces clinical response and remission 
in patients with moderate-to-severe ulcerative colitis. Gas-
troenterology 2014; 146: 85-95; quiz e14-5 [PMID: 23735746 
DOI: 10.1053/j.gastro.2013.05.048]
31 Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson 
A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer 
SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, 
Colombel JF. Colectomy rate comparison after treatment of 
ulcerative colitis with placebo or infliximab. Gastroenterol-
ogy 2009; 137: 1250-1260; quiz 1520 [PMID: 19596014 DOI: 
10.1053/j.gastro.2009.06.061]
32 Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibi-
tors for inflammatory bowel disease. N Engl J Med 2013; 369: 
754-762 [PMID: 23964937 DOI: 10.1056/NEJMct1209614]
33 Bezabeh S, Flowers CM, Kortepeter C, Avigan M. Clinically 
significant liver injury in patients treated with natalizumab. 
Aliment Pharmacol Ther 2010; 31: 1028-1035 [PMID: 20163378 
DOI: 10.1111/j.1365-2036.2010.04262.x]
34 Davern T. Hepatotoxicity of immunomodulator agents and 
the transplant situation. In: Kaplowitz N, Deleve L, editors. 
Drug-induced liver injury. New York: Informa Helathcare, 
2007
35 FDA. Briefing document: Arthritis Advisory Committee. 
Accessed November 2011. Available from: URL: http://
www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.
htm
36 Esteve M, Saro C, González-Huix F, Suarez F, Forné M, 
Viver JM. Chronic hepatitis B reactivation following inflix-
imab therapy in Crohn’s disease patients: need for primary 
prophylaxis. Gut 2004; 53: 1363-1365 [PMID: 15306601]
37 Hoentjen F, van Bodegraven AA. Safety of anti-tumor ne-
crosis factor therapy in inflammatory bowel disease. World J 
Gastroenterol 2009; 15: 2067-2073 [PMID: 19418577]
38 Orlando A, Armuzzi A, Papi C, Annese V, Ardizzone S, 
Biancone L, Bortoli A, Castiglione F, D’Incà R, Gionchetti P, 
Kohn A, Poggioli G, Rizzello F, Vecchi M, Cottone M. The 
Italian Society of Gastroenterology (SIGE) and the Italian 
Group for the study of Inflammatory Bowel Disease (IG-
IBD) Clinical Practice Guidelines: The use of tumor necrosis 
17357 December 14, 2014|Volume 20|Issue 46|WJG|www.wjgnet.com
Rossi RE et al . Tumour-necrosis-factor inhibitors and liver
factor-alpha antagonist therapy in inflammatory bowel 
disease. Dig Liver Dis 2011; 43: 1-20 [PMID: 20843756 DOI: 
10.1016/j.dld.2010.07.010]
39 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, 
Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H, Gran-
inger W, Tilg H, Reinisch W. A decade of infliximab: The 
Austrian evidence based consensus on the safe use of inflix-
imab in inflammatory bowel disease. J Crohns Colitis 2010; 4: 
221-256 [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001]
40 FDA, Center for Drug Evaluation and Research, Arthritis 
Advisory Committee. Safety of TNF Inhibitors, 4 March 
2003 (Transcript). Accessed 18 September 2007. Available 
from: URL: http://www.fda.gov/ohrms/dockets/ac/03/
transcripts/3930T1.htm
41 FDA. Guidelines for Industry-drug Induced Liver Injury: 
Premarketing Clinical Evaluation. Accessed 24 Oct 2007. 
Available from: URL: http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guid-
ances/UCM174090.pdf
42 Ierardi E, Valle ND, Nacchiero MC, De Francesco V, Stoppi-
no G, Panella C. Onset of liver damage after a single admin-
istration of infliximab in a patient with refractory ulcerative 
colitis. Clin Drug Investig 2006; 26: 673-676 [PMID: 17163303]
43 Menghini VV, Arora AS. Infliximab-associated revers-
ible cholestatic liver disease. Mayo Clin Proc 2001; 76: 84-86 
[PMID: 11155419]
44 García Aparicio AM, Rey JR, Sanz AH, Alvarez JS. Success-
ful treatment with etanercept in a patient with hepatotoxic-
ity closely related to infliximab. Clin Rheumatol 2007; 26: 
811-813 [PMID: 16550301]
45 Soto-Fernández S, González-Carro P, De Pedro-Esteban 
A, Legaz-Huidobro ML, Pérez-Roldán F, Roncero García-
Escribano O, Valbuena-González M, Ruiz-Carrillo F. [Inflix-
imab-induced hepatitis in a patient with Crohn’s disease]. 
Gastroenterol Hepatol 2006; 29: 321-322 [PMID: 16733041]
46 Wahie S, Alexandroff A, Reynolds NJ. Hepatitis: a rare, but 
important, complication of infliximab therapy for psoriasis. 
Clin Exp Dermatol 2006; 31: 460-461 [PMID: 16681606]
47 Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept 
tolerance in a patient with previous infliximab-induced hep-
atitis. Clin Rheumatol 2008; 27: 1597-1598 [PMID: 18795397 
DOI: 10.1007/s10067-008-1000-3]
48 Kluger N, Girard C, Guillot B, Bessis D. Efficiency and safe-
ty of etanercept after acute hepatitis induced by infliximab 
for psoriasis. Acta Derm Venereol 2009; 89: 332-334 [PMID: 
19479148]
49 Thiéfin G, Morelet A, Heurgué A, Diebold MD, Eschard 
JP. Infliximab-induced hepatitis: absence of cross-toxicity 
with etanercept. Joint Bone Spine 2008; 75: 737-739 [PMID: 
18693125 DOI: 10.1016/j.jbspin.2007.12.009]
50 Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced 
by infliximab in a patient with rheumatoid arthritis with no 
relapse after switching to etanercept. Clin Rheumatol 2009; 
28: 1001-1003 [PMID: 19370307 DOI: 10.1007/s10067-009-
1179-y]
51 Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, 
Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M. 
Liver injury from tumor necrosis factor-α antagonists: anal-
ysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11: 
558-564.e3 [PMID: 23333219 DOI: 10.1016/j.cgh.2012.12.025]
52 Moum B, Konopski Z, Tufteland KF, Jahnsen J. Occurrence 
of hepatoxicicty and elevated liver enzymes in a Crohn’s 
disease patient treated with infliximab. Inflamm Bowel Dis 
2007; 13: 1584-1586 [PMID: 17663423]
53 Poulin Y, Thérien G. Drug-induced hepatitis and lupus 
during infliximab treatment for psoriasis: case report and 
literature review. J Cutan Med Surg 2010; 14: 100-104 [PMID: 
20338127]
54 Kinnunen U, Färkkilä M, Mäkisalo H. A case report: ul-
cerative colitis, treatment with an antibody against tumor 
necrosis factor (infliximab), and subsequent liver necrosis. 
J Crohns Colitis 2012; 6: 724-727 [PMID: 22398069 DOI: 
10.1016/j.crohns.2012.02.004]
55 Haennig A, Bonnet D, Thebault S, Alric L. Infliximab-
induced acute hepatitis during Crohn’s disease therapy: 
absence of cross-toxicity with adalimumab. Gastroenterol 
Clin Biol 2010; 34: e7-e8 [PMID: 20189334 DOI: 10.1016/
j.gcb.2010.01.016]
56 Caussé S, Bouquin R, Wylomanski S, Flamant M, Joubert 
M, Dréno B, Quéreux G. [Infliximab-induced hepatitis dur-
ing treatment of vulvar Crohn’s disease]. Ann Dermatol 
Venereol 2013; 140: 46-51 [PMID: 23328360 DOI: 10.1016/
j.annder.2012.10.601]
57 Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis 
B reactivation in a chronic hepatitis B surface antigen carrier 
with rheumatoid arthritis treated with infliximab and low 
dose methotrexate. Ann Rheum Dis 2003; 62: 686-687 [PMID: 
12810441]
58 Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant 
hepatitis after infliximab in a patient with hepatitis B virus 
treated for an adult onset still’s disease. J Rheumatol 2003; 30: 
1624-1625 [PMID: 12858469]
59 Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Seri-
ous liver disease induced by infliximab. Clin Rheumatol 2007; 
26: 578-581 [PMID: 16547695]
60 Cravo M, Silva R, Serrano M. Autoimmune hepatitis in-
duced by infliximab in a patient with Crohn’s disease with 
no relapse after switching to adalimumab. BioDrugs 2010; 24 
Suppl 1: 25-27 [PMID: 21175232 DOI: 10.2165/11586210-000
000000-00000]
61 Arai O, Omoto K, Notohara K, Shibata N, Kuboki M, Ikeda 
H. [A case of infliximab-related liver damage -case report 
and literature review]. Nihon Shokakibyo Gakkai Zasshi 2013; 
110: 104-111 [PMID: 23303236]
62 Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Ron-
cucci L. Infliximab-related hepatitis: discussion of a case and 
review of the literature. Intern Emerg Med 2010; 5: 193-200 
[PMID: 20107930 DOI: 10.1007/s11739-009-0342-4]
63 Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis 
with interface inflammation and IgG, IgM, and IgA anti-
double-stranded DNA antibodies following infliximab ther-
apy: comment on the article by Charles et al. Arthritis Rheum 
2001; 44: 1966-1968 [PMID: 11508453]
64 Germano V, Picchianti Diamanti A, Baccano G, Natale E, 
Onetti Muda A, Priori R, Valesini G. Autoimmune hepatitis 
associated with infliximab in a patient with psoriatic arthri-
tis. Ann Rheum Dis 2005; 64: 1519-1520 [PMID: 16162908]
65 Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall 
C. Autoimmune hepatitis following infliximab therapy for 
ankylosing spondylitis. Med J Aust 2007; 187: 524-526 [PMID: 
17979620]
66 Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, 
Lopes J, Costa Santos C. Infliximab-induced lupus-like syn-
drome associated with autoimmune hepatitis. Inflamm Bowel 
Dis 2008; 14: 723-725 [PMID: 17929297]
67 Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis as-
sociated with infliximab in a patient with palmoplantar pus-
tular psoriaisis. Clin Exp Dermatol 2009; 34: 421-422 [PMID: 
19309375 DOI: 10.1111/j.1365-2230.2008.03088.x]
68 Doyle A, Forbes G, Kontorinis N. Autoimmune hepatitis 
during infliximab therapy for Crohn’s disease: a case re-
port. J Crohns Colitis 2011; 5: 253-255 [PMID: 21575891 DOI: 
10.1016/j.crohns.2010.12.007]
69 Goldfeld DA, Verna EC, Lefkowitch J, Swaminath A. Inflix-
imab-induced autoimmune hepatitis with successful switch 
to adalimumab in a patient with Crohn’s disease: the index 
case. Dig Dis Sci 2011; 56: 3386-3388 [PMID: 21597977 DOI: 
10.1007/s10620-011-1748-1]
70 Subramaniam K, Chitturi S, Brown M, Pavli P. Infliximab-in-
duced autoimmune hepatitis in Crohn’s disease treated with 
17358 December 14, 2014|Volume 20|Issue 46|WJG|www.wjgnet.com
Rossi RE et al . Tumour-necrosis-factor inhibitors and liver
budesonide and mycophenolate. Inflamm Bowel Dis 2011; 17: 
E149-E150 [PMID: 21987301 DOI: 10.1002/ibd.21880]
71 Goujon C, Dahel K, Bérard F, Guillot I, Gunera-Saad N, 
Nicolas JF. Autoimmune hepatitis in two psoriasis patients 
treated with inflixmab. J Am Acad Dermatol 2010; 63: e43-e44 
[PMID: 20633783 DOI: 10.1016/j.jaad.2009.02.029]
72 Viganò M, Degasperi E, Aghemo A, Lampertico P, Co-
lombo M. Anti-TNF drugs in patients with hepatitis B or C 
virus infection: safety and clinical management. Expert Opin 
Biol Ther 2012; 12: 193-207 [PMID: 22188392 DOI: 10.1517/14
712598.2012.646986]
73 Carroll MB, Bond MI. Use of tumor necrosis factor-alpha 
inhibitors in patients with chronic hepatitis B infection. 
Semin Arthritis Rheum 2008; 38: 208-217 [PMID: 18221983 
DOI: 10.1016/j.semarthrit.2007.10.011]
74 Antoniou C, Dessinioti C, Katsambas A, Stratigos AJ. El-
evated triglyceride and cholesterol levels after intravenous 
antitumour necrosis factor-alpha therapy in a patient with 
psoriatic arthritis and psoriasis vulgaris. Br J Dermatol 2007; 
156: 1090-1091 [PMID: 17408391]
75 Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, 
Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas 
DT. Modest but sustained increase of serum high density 
lipoprotein cholesterol levels in patients with inflammatory 
arthritides treated with infliximab. J Rheumatol 2006; 33: 
2440-2446 [PMID: 17014005]
76 Castro KR, Aikawa NE, Saad CG, Moraes JC, Medeiros AC, 
Mota LM, Silva CA, Bonfá E, Carvalho JF. Infliximab in-
duces increase in triglyceride levels in psoriatic arthritis pa-
tients. Clin Dev Immunol 2011; 2011: 352686 [PMID: 21804855 
DOI: 10.1155/2011/352686]
77 Koutroubakis IE, Oustamanolakis P, Malliaraki N, Karmiris 
K, Chalkiadakis I, Ganotakis E, Karkavitsas N, Kouroumalis 
EA. Effects of tumor necrosis factor alpha inhibition with 
infliximab on lipid levels and insulin resistance in pa-
tients with inflammatory bowel disease. Eur J Gastroenterol 
Hepatol 2009; 21: 283-288 [PMID: 19279474 DOI: 10.1097/
MEG.0b013e328325d42b]
78 European Association for the Study of Liver. EASL clinical 
practical guidelines: management of alcoholic liver disease. 
J Hepatol 2012; 57: 399-420 [PMID: 22633836 DOI: 10.1016/
j.jhep.2012.04.004]
79 European Association For The Study Of The Liver. EASL 
clinical practice guidelines: Management of chronic hepa-
titis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 
22436845 DOI: 10.1016/j.jhep.2012.02.010]
80 Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Ser-
rano J, Hoofnagle JH. Standardization of nomenclature and 
causality assessment in drug-induced liver injury: summary 
of a clinical research workshop. Hepatology 2010; 52: 730-742 
[PMID: 20564754 DOI: 10.1002/hep.23696]
81 Lee WM, Senior JR. Recognizing drug-induced liver injury: 
current problems, possible solutions. Toxicol Pathol 2005; 33: 
155-164 [PMID: 15805067]
82 Shapiro MA, Lewis JH. Causality assessment of drug-
induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 
2007; 11: 477-505, v [PMID: 17723916]
83 Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Dav-
ern T, Serrano J, Yang H, Rochon J. Causes, clinical features, 
and outcomes from a prospective study of drug-induced 
liver injury in the United States. Gastroenterology 2008; 
135: 1924-1934, 1934.e1-4 [PMID: 18955056 DOI: 10.1053/
j.gastro.2008.09.011]
84 Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky 
HL, Watkins PB, Hayashi PH, Davern TJ, Navarro V, Reddy 
R, Talwalkar JA, Stolz A, Gu J, Barnhart H, Hoofnagle JH. 
Hepatic histological findings in suspected drug-induced 
liver injury: systematic evaluation and clinical associations. 
Hepatology 2014; 59: 661-670 [PMID: 24037963 DOI: 10.1002/
hep.26709]
85 Volta U. Liver dysfunction in celiac disease. Minerva Med 
2008; 99: 619-629 [PMID: 19034259]
P- Reviewer: Desai DC, Goossens N, Yuksel I    S- Editor: Ma N 
L- Editor: A    E- Editor: Ma S
17359 December 14, 2014|Volume 20|Issue 46|WJG|www.wjgnet.com
Rossi RE et al . Tumour-necrosis-factor inhibitors and liver
                                      © 2014 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc






I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
4  6
